DIA’s Pharmacovigilance and Risk Management Strategies Conference provides the foundation for strong strategic planning and practical decision-making in your pharmacovigilance programs. Developed by recognized experts from the biopharmaceutical industry and global regulatory agencies, this conference provides the background, context, and opportunities to discuss current challenges and to problem-solve around issues that matter most to professionals working in the field.

This year’s conference will address the current thinking on predicting and assessing risks such as drug-induced liver injury, and the assessment of expectedness of serious adverse reactions during clinical development. The complexities of assessing benefit-risk balance of today’s therapies, including immunotherapy and other advanced therapies, will be examined. Experts will present approaches and engage in dialogs around more extensive and impactful uses of real world data and generation of RWE for safety assessments. A full-day will be devoted to the development, implementation, and assessment of risk management strategies for drugs approved in multiple regions, with a special in-depth coverage of REMS in the US.

In addition to new developments and updates on regional regulations and guidelines, regulators from the US, EU, and other global regions provide the context and thinking behind evolving requirements.

Connect with WCG at the conference

  • Visit our Booth #10 at the Conference
  • Please see below for a list of WCG’s speaking sessions at the event.

WCG Speaking Session's at DIA's Pharmacovigilance and Risk Management Strategies Conference

Monday, January 27th

Can pharmacovigilance do more to keep patients safe from medication errors?
12:00-1:30 PM
Table #3
Speaker: Angela Pitwood
Vice President, WCG Vigilare